Our Mission

Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.

Upcoming Events

No event has been scheduled

Annual Meetings of Stockholders

June 11, 2025

Clinical Trials

Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1).

Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1). For more information on each clinical trial, please click on the corresponding link below.

Our Product

FDA APPROVED TREATMENT

To Learn More Click Here
Nerlynx®
Nerlynx®